The protective role of DPP4 inhibitors in atherosclerosis
Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. G...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2020-05, Vol.875, p.173037-173037, Article 173037 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 173037 |
---|---|
container_issue | |
container_start_page | 173037 |
container_title | European journal of pharmacology |
container_volume | 875 |
creator | Liu, Hengdao Guo, Lingli Xing, Junhui Li, Peicheng Sang, Haiqiang Hu, Xiaofang Du, Yunpeng Zhao, Liangping Song, Ruipeng Gu, Heping |
description | Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed. |
doi_str_mv | 10.1016/j.ejphar.2020.173037 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2365205287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299920301291</els_id><sourcerecordid>2365205287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEYmPwDxDqkUuH89UsFyTEtzSJHcY5SlNXzdStI-km8e_J1MGRi21Zr_3aDyHXFKYUaHG3muJq29gwZcBSS3Hg6oSM6UzpHBRlp2QMQEXOtNYjchHjCgCkZvKcjDgDrQpZjIleNphtQ9ej6_0es9C1mHV19rRYiMxvGl_6vgsxlZntGwxddO0h-nhJzmrbRrw65gn5fHlePr7l84_X98eHee54wfpcWFsqFEJQZ6GyUlu0lXBWKQBNZ4BM89pKW1ZYY8nAAadCUxCyLAoAxifkdtibrvzaYezN2keHbWs32O2iYbyQDCSbqSQVg9SlC2PA2myDX9vwbSiYAzSzMgM0c4BmBmhp7ObosCvXWP0N_VJKgvtBgOnPvcdgovO4cVj5kLiZqvP_O_wAbrZ-Uw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2365205287</pqid></control><display><type>article</type><title>The protective role of DPP4 inhibitors in atherosclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Liu, Hengdao ; Guo, Lingli ; Xing, Junhui ; Li, Peicheng ; Sang, Haiqiang ; Hu, Xiaofang ; Du, Yunpeng ; Zhao, Liangping ; Song, Ruipeng ; Gu, Heping</creator><creatorcontrib>Liu, Hengdao ; Guo, Lingli ; Xing, Junhui ; Li, Peicheng ; Sang, Haiqiang ; Hu, Xiaofang ; Du, Yunpeng ; Zhao, Liangping ; Song, Ruipeng ; Gu, Heping</creatorcontrib><description>Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2020.173037</identifier><identifier>PMID: 32097656</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Atherosclerosis - blood ; Atherosclerosis - etiology ; Atherosclerosis - pathology ; Atherosclerosis - prevention & control ; Blood Pressure - drug effects ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetic chronic vascular complications ; Dipeptidyl Peptidase 4 - blood ; Dipeptidyl Peptidase 4 - metabolism ; Dipeptidyl-Peptidase IV Inhibitors - pharmacology ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Disease Models, Animal ; DPP4 inhibitors ; Endothelial Cells - drug effects ; Endothelial Cells - pathology ; Endothelium, Vascular - cytology ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - pathology ; Humans ; Lipid Metabolism - drug effects ; Lipids - blood ; Oxidative Stress - drug effects ; Protective role ; Risk Factors</subject><ispartof>European journal of pharmacology, 2020-05, Vol.875, p.173037-173037, Article 173037</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</citedby><cites>FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299920301291$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32097656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Hengdao</creatorcontrib><creatorcontrib>Guo, Lingli</creatorcontrib><creatorcontrib>Xing, Junhui</creatorcontrib><creatorcontrib>Li, Peicheng</creatorcontrib><creatorcontrib>Sang, Haiqiang</creatorcontrib><creatorcontrib>Hu, Xiaofang</creatorcontrib><creatorcontrib>Du, Yunpeng</creatorcontrib><creatorcontrib>Zhao, Liangping</creatorcontrib><creatorcontrib>Song, Ruipeng</creatorcontrib><creatorcontrib>Gu, Heping</creatorcontrib><title>The protective role of DPP4 inhibitors in atherosclerosis</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.</description><subject>Animals</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - etiology</subject><subject>Atherosclerosis - pathology</subject><subject>Atherosclerosis - prevention & control</subject><subject>Blood Pressure - drug effects</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetic chronic vascular complications</subject><subject>Dipeptidyl Peptidase 4 - blood</subject><subject>Dipeptidyl Peptidase 4 - metabolism</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>DPP4 inhibitors</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - pathology</subject><subject>Endothelium, Vascular - cytology</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - pathology</subject><subject>Humans</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipids - blood</subject><subject>Oxidative Stress - drug effects</subject><subject>Protective role</subject><subject>Risk Factors</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PwzAMhiMEYmPwDxDqkUuH89UsFyTEtzSJHcY5SlNXzdStI-km8e_J1MGRi21Zr_3aDyHXFKYUaHG3muJq29gwZcBSS3Hg6oSM6UzpHBRlp2QMQEXOtNYjchHjCgCkZvKcjDgDrQpZjIleNphtQ9ej6_0es9C1mHV19rRYiMxvGl_6vgsxlZntGwxddO0h-nhJzmrbRrw65gn5fHlePr7l84_X98eHee54wfpcWFsqFEJQZ6GyUlu0lXBWKQBNZ4BM89pKW1ZYY8nAAadCUxCyLAoAxifkdtibrvzaYezN2keHbWs32O2iYbyQDCSbqSQVg9SlC2PA2myDX9vwbSiYAzSzMgM0c4BmBmhp7ObosCvXWP0N_VJKgvtBgOnPvcdgovO4cVj5kLiZqvP_O_wAbrZ-Uw</recordid><startdate>20200515</startdate><enddate>20200515</enddate><creator>Liu, Hengdao</creator><creator>Guo, Lingli</creator><creator>Xing, Junhui</creator><creator>Li, Peicheng</creator><creator>Sang, Haiqiang</creator><creator>Hu, Xiaofang</creator><creator>Du, Yunpeng</creator><creator>Zhao, Liangping</creator><creator>Song, Ruipeng</creator><creator>Gu, Heping</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200515</creationdate><title>The protective role of DPP4 inhibitors in atherosclerosis</title><author>Liu, Hengdao ; Guo, Lingli ; Xing, Junhui ; Li, Peicheng ; Sang, Haiqiang ; Hu, Xiaofang ; Du, Yunpeng ; Zhao, Liangping ; Song, Ruipeng ; Gu, Heping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - etiology</topic><topic>Atherosclerosis - pathology</topic><topic>Atherosclerosis - prevention & control</topic><topic>Blood Pressure - drug effects</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetic chronic vascular complications</topic><topic>Dipeptidyl Peptidase 4 - blood</topic><topic>Dipeptidyl Peptidase 4 - metabolism</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>DPP4 inhibitors</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - pathology</topic><topic>Endothelium, Vascular - cytology</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - pathology</topic><topic>Humans</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipids - blood</topic><topic>Oxidative Stress - drug effects</topic><topic>Protective role</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Hengdao</creatorcontrib><creatorcontrib>Guo, Lingli</creatorcontrib><creatorcontrib>Xing, Junhui</creatorcontrib><creatorcontrib>Li, Peicheng</creatorcontrib><creatorcontrib>Sang, Haiqiang</creatorcontrib><creatorcontrib>Hu, Xiaofang</creatorcontrib><creatorcontrib>Du, Yunpeng</creatorcontrib><creatorcontrib>Zhao, Liangping</creatorcontrib><creatorcontrib>Song, Ruipeng</creatorcontrib><creatorcontrib>Gu, Heping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Hengdao</au><au>Guo, Lingli</au><au>Xing, Junhui</au><au>Li, Peicheng</au><au>Sang, Haiqiang</au><au>Hu, Xiaofang</au><au>Du, Yunpeng</au><au>Zhao, Liangping</au><au>Song, Ruipeng</au><au>Gu, Heping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The protective role of DPP4 inhibitors in atherosclerosis</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2020-05-15</date><risdate>2020</risdate><volume>875</volume><spage>173037</spage><epage>173037</epage><pages>173037-173037</pages><artnum>173037</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32097656</pmid><doi>10.1016/j.ejphar.2020.173037</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2020-05, Vol.875, p.173037-173037, Article 173037 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_2365205287 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Atherosclerosis - blood Atherosclerosis - etiology Atherosclerosis - pathology Atherosclerosis - prevention & control Blood Pressure - drug effects Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic chronic vascular complications Dipeptidyl Peptidase 4 - blood Dipeptidyl Peptidase 4 - metabolism Dipeptidyl-Peptidase IV Inhibitors - pharmacology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Disease Models, Animal DPP4 inhibitors Endothelial Cells - drug effects Endothelial Cells - pathology Endothelium, Vascular - cytology Endothelium, Vascular - drug effects Endothelium, Vascular - pathology Humans Lipid Metabolism - drug effects Lipids - blood Oxidative Stress - drug effects Protective role Risk Factors |
title | The protective role of DPP4 inhibitors in atherosclerosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T04%3A58%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20protective%20role%20of%20DPP4%20inhibitors%20in%20atherosclerosis&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Liu,%20Hengdao&rft.date=2020-05-15&rft.volume=875&rft.spage=173037&rft.epage=173037&rft.pages=173037-173037&rft.artnum=173037&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2020.173037&rft_dat=%3Cproquest_cross%3E2365205287%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2365205287&rft_id=info:pmid/32097656&rft_els_id=S0014299920301291&rfr_iscdi=true |